サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1405868

解毒剤の市場規模、シェア、動向分析レポート：タイプ別、投与経路別、流通チャネル別、最終用途別、地域別、セグメント予測、2024年～2030年

Antidote Market Size, Share & Trends Analysis Report By Type (Chemical Antidote, Physical Antidote, Pharmacological Antidote), By Route Of Administration, By Distribution Channel, By End-use, By Region, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 180 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
解毒剤の市場規模、シェア、動向分析レポート：タイプ別、投与経路別、流通チャネル別、最終用途別、地域別、セグメント予測、2024年～2030年
出版日: 2023年12月18日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

解毒剤市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の解毒剤市場は2024年から2030年にかけてCAGR 7.60%で拡大し、2030年までには35億8,000万米ドルに達する見込みです。

この市場を牽引しているのは、主にヘビ咬傷の発生率とそれに伴う副作用です。例えば、2023年にPLOSに掲載された調査論文によると、インドではヘビに咬まれたことが原因で約58,000人の死亡が記録されています。

さらに、薬物の過剰摂取の急増が市場を牽引しています。米国の保健社会福祉省によると、米国では2021年に約106,699人の薬物過剰摂取による死亡が記録されています。解毒剤は、特定の薬物の毒性作用を中和または逆転させる働きをします。例えば、ナロキソンは、オピオイドの過剰摂取による呼吸抑制や鎮静を速やかに回復させるために一般的に使用されています。解毒剤のこうした機能が市場の成長を後押ししています。

さらに、職業中毒の有病率の上昇も、解毒剤のニーズの増加に寄与しています。オピオイド過剰摂取、青酸中毒、一酸化炭素中毒、鉛中毒、有機リン酸中毒などの発生率の増加により、解毒剤の用途が増加しています。例えば、NCBIの調査論文によると、2020年12月の推定では、世界中で約3億8,500万件の意図しない農薬中毒が発生し、うち1万1,000人が死亡しています。このため、予測期間中に市場は急成長すると予想されます。

いくつかの中毒事例を治療するための新規解毒薬の研究開発活動、発売、承認の増加は、予測期間中の成長を加速すると予想されます。例えば、2023年8月、Rising Pharmaceuticalsは、鉛中毒治療のためのエデト酸カルシウム二ナトリウム注射剤の発売と承認を発表しました。また、2021年4月には、Hikma Pharmaceuticals PLCがオピオイド過剰摂取治療用のKLOXXADO TM点鼻スプレーの米国承認を取得しました。主要事業者によるこのような戦略的イニシアチブは、市場を押し上げると予想されます。

さらに、解毒剤と薬剤に関する知識を高めるための政府の取り組みに助けられ、毒物の特定に関する認識を広めるための多くの啓発活動が、市場全体の成長を促進すると予想されます。しかし、製造上の問題、規制上の障害、あるいは経済的要因により、解毒剤の入手可能性が制限されると、救命のための解毒剤へのアクセスが制限される可能性があります。特定の解毒剤のコストが高いことが経済的な障壁となる可能性もあります。さらに、保管の必要性、保存期間の制限、専門的な知識と訓練の必要性などが、解毒剤の応用を制限することがあります。一方、毒物中毒や毒物曝露の管理における入手可能性、有効性、安全性の向上を目指した研究開発が進行中であり、近い将来、市場に有利な機会を提供すると予想されます。

解毒剤市場レポートハイライト

  • タイプ別では、化学的解毒剤が2023年の解毒剤市場を独占しました。
  • 投与経路別では、注射剤が迅速な作用と高い特異性により、2023年の解毒剤市場の最大セグメントシェアを占めました。
  • 販売チャネル別では、病院薬局が2023年の市場を独占しました。この成長は、病院薬局を通じて解毒剤を容易に入手できるなど、多くの要因によるものと考えられます。
  • 最終用途別では、病院が2023年に最大のシェアを占めました。病院での入院や治療の増加が全体的な成長を促進しています。
  • 北米は2023年に33.57％のシェアを占め、強い地域的地位を確立しています。これは、主要事業者の存在、中毒発生率の上昇、同地域における研究開発活動の増加によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
  • 市場促進要因
  • 市場抑制要因分析
  • 事業環境分析
    • SWOT分析：要因別（政治・法律、経済・技術）
    • ポーターのファイブフォース分析
    • COVID-19の影響分析

第4章 タイプのビジネス分析

  • 解毒剤市場：タイプの変動分析
  • 化学的解毒剤
    • 化学的解毒剤市場、2018年～2030年
  • 物理的解毒剤
    • 物理的解毒剤市場、2018年～2030年
  • 薬理学的解毒剤
    • 薬理学的解毒剤市場、2018年～2030年

第5章 投与経路のビジネス分析

  • 解毒剤市場：投与変動分析
  • オーラル
    • オーラル市場、2018年～2030年
  • 局所
    • 局所市場、2018年～2030年
  • 注射剤
    • 注射剤市場、2018年～2030年
  • その他
    • その他市場、2018年～2030年

第6章 流通チャネルのビジネス分析

  • 解毒剤市場：流通チャネルの変動分析
  • 病院薬局
    • 病院薬局市場、2018年～2030年
  • 小売薬局
    • 小売薬局市場、2018年～2030年
  • オンライン薬局
    • オンライン薬局市場、2018年～2030年

第7章 最終用途ビジネス分析

  • 解毒剤市場：流通チャネルの変動分析
  • 病院
    • 病院市場、2018年～2030年
  • ホームケア
    • ホームケア市場、2018年～2030年
  • 専門クリニック
    • 専門クリニック市場、2018年～2030年
  • その他
    • その他市場、2018年～2030年

第8章 地域ビジネス分析

  • 地域別の解毒剤市場シェア、2023年と2030年
  • 北米
    • 北米の解毒剤市場、2018年～2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州の解毒剤市場、2018年～2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • アジア太平洋地域の解毒剤市場、2018年～2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ラテンアメリカの解毒剤市場、2018年～2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 中東・アフリカの解毒剤市場、2018年～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 競合情勢

  • 参入企業の概要
  • 財務実績
  • 参入企業
    • マーケットリーダー
    • 解毒剤市場シェア分析、2023年
    • 企業プロファイル
    • 戦略マッピング
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 3 Global Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 4 Global Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 Global Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 6 Global Antidote Market, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Antidote Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 9 North America Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 North America Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 North America Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 12 U.S. Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 U.S. Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 Canada Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Canada Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Canada Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Europe Antidote Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 23 Europe Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Europe Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 25 Germany Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 26 Germany Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 Germany Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Germany Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 29 UK Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 30 UK Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 UK Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 UK Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 33 France Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 34 France Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 France Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 France Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 37 Italy Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 38 Italy Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 Italy Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Italy Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Spain Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 Spain Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Spain Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Spain Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Denmark Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 46 Denmark Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 47 Denmark Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Denmark Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 49 Sweden Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 50 Sweden Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 Sweden Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Sweden Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 53 Norway Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 54 Norway Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 Norway Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Norway Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Antidote Market, by Country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Antidote Market, by End-use, 2018 - 2030 (USD Million)
  • Table 62 China Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 63 China Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 China Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 China Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 66 Japan Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 67 Japan Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Japan Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Japan Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 70 India Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 71 India Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 72 India Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 India Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 74 South Korea Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 75 South Korea Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 76 South Korea Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77 South Korea Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 78 Australia Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 79 Australia Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 80 Australia Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 81 Australia Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 82 Thailand Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 83 Thailand Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 84 Thailand Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 85 Thailand Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 86 Latin America Antidote Market, by Country, 2018 - 2030 (USD Million)
  • Table 87 Latin America Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 88 Latin America Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 89 Latin America Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 90 Latin America Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 91 Brazil Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 92 Brazil Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 93 Brazil Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 94 Brazil Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 95 Mexico Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 96 Mexico Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 97 Mexico Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 98 Mexico Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 99 Argentina Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 100 Argentina Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 101 Argentina Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 102 Argentina Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 108 South Africa Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 109 South Africa Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 110 South Africa Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 111 South Africa Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 116 UAE Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 117 UAE Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 118 UAE Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 119 UAE Antidote Market, by End Use, 2018 - 2030 (USD Million)
  • Table 120 Kuwait Antidote Market, by Type, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Antidote Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Antidote Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Antidote Market, by End Use, 2018 - 2030 (USD Million) 

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Antidote Market Segmentation
  • Fig. 8 Market Snapshot, 2023
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 PESTEL Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Global Antidote Market: Type Movement Analysis
  • Fig. 15 Global Antidote Market, by Chemical Antidote, 2018 - 2030 (USD Million)
  • Fig. 16 Global Antidote Market, by Physical Antidote, 2018 - 2030 (USD Million)
  • Fig. 17 Global Antidote Market, by Pharmacological Antidote, 2018 - 2030 (USD Million)
  • Fig. 18 Global Antidote Market: Route of Administration Movement Analysis
  • Fig. 19 Global Antidote Market, by Oral, 2018 - 2030 (USD Million)
  • Fig. 20 Global Antidote Market, by Topical, 2018 - 2030 (USD Million)
  • Fig. 21 Global Antidote Market, by Injectable, 2018 - 2030 (USD Million)
  • Fig. 22 Global Antidote Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 23 Global Antidote Market: Distribution Channel Movement Analysis
  • Fig. 24 Global Antidote Market, by Hospital Pharmacies 2018 - 2030 (USD Million)
  • Fig. 25 Global Antidote Market, by Retail Pharmacies 2018 - 2030 (USD Million)
  • Fig. 26 Global Antidote Market, by Online Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 27 Global Antidote Market: End Use Movement Analysis
  • Fig. 28 Global Antidote Market, by Hospitals 2018 - 2030 (USD Million)
  • Fig. 29 Global Antidote Market, by Homecare 2018 - 2030 (USD Million)
  • Fig. 30 Global Antidote Market, by Speciality Clinics, 2018 - 2030 (USD Million)
  • Fig. 31 Global Antidote Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 32 Regional Marketplace: Key Takeaways
  • Fig. 33 Regional Outlook, 2023 & 2030
  • Fig. 34 Global Antidote Market: Region Movement Analysis
  • Fig. 35 North America Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 40 UK Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 41 France Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 49 China Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 50 India Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East and Africa Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 60 Saudi Arabia Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 61 UAE Antidote Market, 2018 - 2030 (USD Million)
  • Fig. 62 Kuwait Antidote Market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-169-2

Antidote Market Growth & Trends:

The global antidote market is expected to reach USD 3.58 billion by 2030, expanding at a CAGR of 7.60% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the incidence of snakebites and the adverse effects associated with them. For instance, according to a research article published on PLOS in 2023, approximately 58,000 deaths were recorded in India due to snake bites.

Moreover, surge in number of drug overdoses is driving the market. According to U.S. Department of Health & Human Services, about 106,699 drug overdose deaths were recorded in the U.S. in 2021. Antidote works to neutralize or reverse the toxic effects of specific drug. For instance, Naloxone is commonly used to reverse respiratory sedation and depression in opioid overdose rapidly. These capabilities of antidote are boosting the market growth.

Furthermore, rising prevalence of occupational poisoning is also contributing to the increased need for antidotes. Applications of antidote is rising owing to the growing incidence of opioid overdose, cyanide poisoning, carbon monoxide poisoning, lead poisoning, and organophosphate poisoning among others. For instance, as per NCBI research article, estimates in December 2020, approximately 385 million instances of unintentional pesticide poisoning occurred across the globe, including 11,000 deaths. Thus, the market is expected to grow rapidly during the forecast period.

Increasing R&D activities, launch, and approval of novel antidote drugs for treating several poisoning cases are anticipated to accelerate the growth during the projected period. For instance, in August 2023, Rising Pharmaceuticals, announced the launch and approval of Edetate calcium disodium injection for treating lead poisoning. In addition, in April 2021, Hikma Pharmaceuticals PLC, received U.S. approval of KLOXXADO TM nasal spray for treating opioid overdose. Such strategic initiatives by the key operating players are expected to boost the market.

Furthermore, a number of awareness activities to spread awareness regarding the identification of toxins aided with government initiatives to increase knowledge of antidotes and drugs is expected to drive the growth of overall market. However, limited availability of antidote due to manufacturing issues, regulatory obstacles, or economic factors can restrict access to life-saving antidotes. High costs of certain antidotes may pose financial barriers. In addition, storage requirements, shelf life limitations, and the need for specialized knowledge and training may restrict the applications of antidote. On the other hand, ongoing research and development efforts aim to improve availability, effectiveness, and safety in managing poisonings and toxic exposures are anticipated to offer lucrative opportunities for the market in the near future.

Antidote Market Report Highlights:

  • By type, the chemical antidote dominated the antidote market in 2023 attributable to precise dosing, minimized compilations, and consistent outcomes
  • By route of administration, injectionheld the largest segment share of antidote market 2023, attributable to their rapid action and high specificity
  • By distribution channel, hospital pharmacies dominated the market in 2023. This growth can be attributed to numerous factors, including easy accessibility of antidote through hospital pharmacies
  • By end-use, the hospitals held the largest share in 2023. Increasing number of hospitalizations and treatments in the hospital settings is propelling overall growth
  • North America has established a strong regional position with a 33.57% share in 2023, owing to presence of key operating players, rising incidence of poisoning, and increasing research and development activities in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
  • 3.5. Market Restraint Analysis
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Antidote Market: Type Movement Analysis
  • 4.2. Chemical Antidote
    • 4.2.1. Chemical Antidote Market, 2018 - 2030 (USD Million)
  • 4.3. Physical Antidote
    • 4.3.1. Physical Antidote Market, 2018 - 2030 (USD Million)
  • 4.4. Pharmacological Antidote
    • 4.4.1. Pharmacological Antidote Market, 2018 - 2030 (USD Million)

Chapter 5. Route of Administration Business Analysis

  • 5.1. Antidote Market: Route of Administration Movement Analysis
  • 5.2. Oral
    • 5.2.1. Oral Market, 2018 - 2030 (USD Million)
  • 5.3. Topical
    • 5.3.1. Topical Market, 2018 - 2030 (USD Million)
  • 5.4. Injectable
    • 5.4.1. Injectable Market, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis

  • 6.1. Antidote Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacies
    • 6.2.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacies
    • 6.3.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.4. Online Pharmacies
    • 6.4.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Antidote Market: Distribution Channel Movement Analysis
  • 7.2. Hospitals
    • 7.2.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 7.3. Homecare
    • 7.3.1. Homecare Market, 2018 - 2030 (USD Million)
  • 7.4. Specialty Clinics
    • 7.4.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
  • 7.5. Others
    • 7.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Antidote Market Share By Region, 2023 & 2030
  • 8.2. North America
    • 8.2.1. North America Antidote market, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement Scenario
      • 8.2.2.6. U.S. Antidote market, 2018 - 2030 (USD MILLION)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. Canada Antidote market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Antidote market, 2018 - 2030 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Competitive Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
      • 8.3.2.6. Germany Antidote market, 2018 - 2030 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. UK Antidote market, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. France Antidote market, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. Italy Antidote market, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Spain Antidote market, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Denmark Antidote market, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Sweden Antidote market, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Norway Antidote market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Antidote market, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Competitive Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
      • 8.4.2.6. Japan Antidote market, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. China Antidote market, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. India Antidote market, 2018 - 2030 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. South Korea Antidote market, 2018 - 2030 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. Australia Antidote market, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Thailand Antidote market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Antidote market, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
      • 8.5.2.6. Brazil Antidote market, 2018 - 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Mexico Antidote market, 2018 - 2030 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Reimbursement Scenario
      • 8.5.4.6. Argentina Antidote market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA Antidote market, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Competitive Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
      • 8.6.2.6. South Africa Antidote market, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. Saudi Arabia Antidote market, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. UAE Antidote market, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. Kuwait Antidote market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant's overview
  • 9.2. Financial performance
  • 9.3. Participant categorization
    • 9.3.1. Market Leaders
    • 9.3.2. Antidote market Share Analysis, 2023
    • 9.3.3. Company Profiles
      • 9.3.3.1. Pfizer Inc
      • 9.3.3.1.1. Company Overview
      • 9.3.3.1.2. Financial Performance
      • 9.3.3.1.3. Product Benchmarking
      • 9.3.3.1.4. Strategic Initiatives
      • 9.3.3.2. Hikma Pharmaceuticals PLC
      • 9.3.3.2.1. Company Overview
      • 9.3.3.2.2. Financial Performance
      • 9.3.3.2.3. Product Benchmarking
      • 9.3.3.2.4. Strategic Initiatives
      • 9.3.3.3. Dr. Reddy's Laboratories Ltd
      • 9.3.3.3.1. Company Overview
      • 9.3.3.3.2. Financial Performance
      • 9.3.3.3.3. Product Benchmarking
      • 9.3.3.3.4. Strategic Initiatives
      • 9.3.3.4. Mylan N.V.
      • 9.3.3.4.1. Company Overview
      • 9.3.3.4.2. Financial Performance
      • 9.3.3.4.3. Product Benchmarking
      • 9.3.3.4.4. Strategic Initiatives
      • 9.3.3.5. Fresenius Kabi AG
      • 9.3.3.5.1. Company Overview
      • 9.3.3.5.2. Financial Performance
      • 9.3.3.5.3. Product Benchmarking
      • 9.3.3.5.4. Strategic Initiatives
      • 9.3.3.6. Zydus Lifesciences Ltd
      • 9.3.3.6.1. Company Overview
      • 9.3.3.6.2. Financial Performance
      • 9.3.3.6.3. Product Benchmarking
      • 9.3.3.6.4. Strategic Initiatives
      • 9.3.3.7. Endo International plc
      • 9.3.3.7.1. Company Overview
      • 9.3.3.7.2. Financial Performance
      • 9.3.3.7.3. Product Benchmarking
      • 9.3.3.7.4. Strategic Initiatives
      • 9.3.3.8. Novartis AG
      • 9.3.3.8.1. Company Overview
      • 9.3.3.8.2. Financial Performance
      • 9.3.3.8.3. Product Benchmarking
      • 9.3.3.8.4. Strategic Initiatives
      • 9.3.3.9. Baxter International, Inc.
      • 9.3.3.9.1. Company Overview
      • 9.3.3.9.2. Financial Performance
      • 9.3.3.9.3. Product Benchmarking
      • 9.3.3.9.4. Strategic Initiatives
      • 9.3.3.10. EMERGENT
      • 9.3.3.10.1. Company Overview
      • 9.3.3.10.2. Financial Performance
      • 9.3.3.10.3. Product Benchmarking
      • 9.3.3.10.4. Strategic Initiatives
    • 9.3.4. Strategy Mapping
      • 9.3.4.1. Expansion
      • 9.3.4.2. Acquisition
      • 9.3.4.3. Collaborations
      • 9.3.4.4. Disease Type/Drug Class Launch
      • 9.3.4.5. Partnerships
      • 9.3.4.6. Others